嘉应制药(002198) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥93,430,702.81, representing a 19.08% increase compared to ¥78,461,064.68 in the same period last year[8] - Net profit attributable to shareholders was ¥8,456,582.31, up 7.92% from ¥7,835,931.73 year-on-year[8] - Basic earnings per share increased to ¥0.0167, reflecting an 8.44% rise from ¥0.0154[8] - The estimated net profit attributable to shareholders for the first half of 2018 is expected to be between 10.00% and 25.00% higher than the same period last year, translating to a range of 10.89 million to 12.375 million yuan[20] - The net profit for the first half of 2017 attributable to shareholders was 9.90 million yuan[20] - The expected growth in net profit for the first half of 2018 is mainly attributed to market conditions and increased sales promotion efforts, leading to higher operating revenue compared to the previous year[20] Cash Flow - The net cash flow from operating activities was -¥6,698,245.46, an improvement of 56.08% from -¥15,249,516.29 in the previous year[8] - The net cash flow from operating activities increased by 8.5513 million yuan, a growth of 56.08%, primarily due to an increase in cash received from sales of goods[17] - The net cash flow from financing activities decreased by 1.8046 million yuan, a decline of 6030.50%, primarily due to increased repayments of bank loans by Jiaying Pharmaceutical[17] - Cash paid for debt repayment increased by 1.81 million yuan, a rise of 182.83%, mainly due to an increase in bank loan repayments by Jiaying Pharmaceutical during the reporting period[17] Assets and Shareholder Information - Total assets at the end of the reporting period were ¥853,534,369.15, down 2.63% from ¥876,610,240.21 at the end of the previous year[8] - The number of ordinary shareholders at the end of the reporting period was 17,955, with the top ten shareholders holding a combined 56.67% of shares[11] Costs and Expenses - Operating costs increased by ¥11,885,600, a 49.65% rise due to higher raw material and labor costs[16] - Financial expenses rose by ¥191,000, a 46.53% increase attributed to higher interest on short-term bank loans[16] Return on Equity - The company's weighted average return on equity was 0.98%, an increase of 0.19% compared to 0.79% in the previous year[8] Other Income - The company received government subsidies amounting to ¥184,500, contributing to a significant increase in other income[9]